Congratulations to Yael Baratz‘s client CytoReason, who have entered into a Collaboration Agreement with Pfizer Inc.
CytoReason will potentially receive tens of millions of US$ for technology access fees, #research support and certain success-based payments. CytoReason is a leader in machine learning for drug discovery and development.
Their technology has to date yielded 2 pending patents, 10 commercial and scientific collaborations and 16 peer reviewed publications.
For the full article, click HERE
